We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Promising Early Results for Immunotherapy-Antiangiogenesis Combination.
- Authors
Garber, Ken
- Abstract
The article discusses research on combining the drugs ipilimumab and bevacizumab in treating metastatic melanoma, published in the July 2014 issue of "Cancer Immunology Research." Results discussed include the possible influence of angiogenesis inhibitors on antitumor effects, the effectiveness of bevacizumab-ipilimumab combination, and the approval of pem-brolizumab antibody from pharmaceutical firm Merck by the U.S. Food and Drug Administration for treating metastatic melanoma.
- Subjects
COMBINATION drug therapy; BEVACIZUMAB; METASTASIS; MELANOMA treatment; CANCER treatment; DRUG approval; MERCK &; Co. Inc.; UNITED States. Food &; Drug Administration
- Publication
JNCI: Journal of the National Cancer Institute, 2014, Vol 106, Issue 11, p2
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/dju392